Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | ESRRB | O95718 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESRRG | P62508 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877401 | 1.00 | HRH3 (0.41) | HRH3ACKR3ESRRBESR1ESRRG | |
| SCHEMBL4875575 | 1.00 | HRH3 (0.41) | HRH3ACKR3ESRRBESR1ESRRG | |
| SCHEMBL4876154 | 0.91 | MAPK14 (0.41) | HRH3ACKR3ESRRBESR1ESRRG | |
| SCHEMBL4876150 | 0.91 | MAPK14 (0.41) | HRH3ACKR3ESRRBESR1ESRRG | |
| SCHEMBL4875287 | 0.91 | KMT2A (0.40) | HRH3ACKR3MAPK14HSD11B1MAPK13 | |
| SCHEMBL4875278 | 0.91 | KMT2A (0.40) | HRH3ACKR3MAPK14HSD11B1MAPK13 | |
| SCHEMBL4872678 | 0.88 | L3MBTL1 (0.35) | KCNH2MAPK14HSD11B1KMT2A | |
| SCHEMBL4869395 | 0.88 | L3MBTL1 (0.35) | KCNH2MAPK14HSD11B1KMT2A | |
| SCHEMBL4869399 | 0.88 | L3MBTL1 (0.35) | KCNH2MAPK14HSD11B1KMT2A | |
| SCHEMBL4874114 | 0.88 | KMT2A (0.37) | HRH3ACKR3HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | HRH3 3264/4885ACKR3 94/4885ESRRB 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.